> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Report Details FDA Drug Safety Efforts
- URL: https://www.fdaweb.com/report-details-fda-drug-safety-efforts/
- Published: 2021-02-11T12:00:00.000Z
- Updated: 2026-09-14T16:46:22.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148650

*CDER Drug Safety Priorities 2020*, the sixth annual report detailing the Center’s safety programs and activities, “highlights key safety-related milestones and accomplishments of 2020 and focuses on the programs and initiatives at the core of CDER’s drug safety operations,” the [report](https://www.fda.gov/drugs/drug-safety-and-availability/advances-fdas-drug-safety-programs?ref=fdaweb.com) says. It also looks at the many ways CDER has been involved in promoting and protecting public health during the SARS-CoV-2 Covid-19 pandemic.

CDER acting director **Patrizia Cavazzoni** says CDER’s Covid-19 efforts included assessing the safety of products used to treat and prevent Covid-19, monitoring the medical supply chain to prevent supply interruptions or shortages of the medicines people need, and taking action against fraudulent unapproved and potentially harmful Covid-19 products.